The Talcum Powder Lawsuit Helpline is always searching for helpful articles for our readers. With so much news about Talcum Powder lawsuits we have all been wondering about the link between use of talcum powder and a diagnosis of fallopian tube cancer and ovarian cancer. There have been numerous lawsuits in the news. We are sharing this with our readers.
Evidence Points to Fallopian-tube Origins of Ovarian Cancer
It has been noted in many studies that the talc from the powder can travel thru the fallopian tubes and end up in the ovaries resulting in the dreaded disease. But, what is the link between fallopian tube cancer and ovarian cancer? The following article explores the question
Most cases of high-grade serous cancer (HSGC) ― the most lethal form of ovarian cancer ― arise from the fallopian tubes rather than the ovaries, concludes a literature review published in the April issue of Cancer Prevention Research.
“There has been a major breakthrough in our understanding of the origin of ovarian cancer with the identification of the fallopian tubes as the major source of the cancer,” commented first author Mary Daly, MD, head of the Genetics Risk Assessment Division of Fox Chase Cancer Center in Philadelphia, Pennsylvania. She even suggested that in the future, ovarian cancer may be described as fallopian tube cancer.
“This raises the possibility of altering our risk-reducing surgery approach, specifically, by removing the fallopian tubes first, while a woman is still premenopausal, and then removing the ovaries at the time of onset of menopause,” Dr Daly explained. “This would spare women the side effects and long-term health risks associated with early surgical menopause.”
For women with hereditary risk for ovarian cancer, such as those with BRCA1/2 mutations, the standard of care has been removal of both ovaries and fallopian tubes (bilateral salpingo- oopherectomy [BSO]). Although this procedure reduces the risk for ovarian cancer, it can affect quality of life, precipitate early menopause, cause sexual dysfunction, and contribute to increased risk for cardiovascular disease, osteoporosis, and all-cause mortality.
Because HSGC constitutes the most common form of ovarian cancer among women with high genetic risk, the new approach (bilateral salpingectomy with ovarian retention [BSOR]) could also have a “large impact” on ovarian cancer mortality, Dr Daly and colleagues write in the article.
BSOR could also reduce ovarian cancer risk in women at average risk for ovarian cancer who are undergoing hysterectomy for benign conditions, such as fibroids. About 600,000 women undergo hysterectomies in the United States each year. Fifteen percent of women who have had a hysterectomy develop ovarian cancer, according to background information in the article.
However, in a related editorial, Mark Greene, MD, and Phuong Mai, MD, from the Division of Cancer Epidemiology and Genetics at the National Cancer Institute, in Bethesda, Maryland, state, “in our view, BSOR is an investigational procedure that should not be routinely implemented in high-risk women until its risks and benefits are more clearly defined.”
The editorialists call for more research on the outcomes of such surgery, including impact on quality of life and on ovarian function. But they are pleased to see research moving the field forward. Recalling that in the past, when ovaries were removed prophylactically, the fallopian tubes were often left behind, they note that the current standard is to remove both ovaries and fallopian tubes. This latest research points to the importance of the fallopian tubes in ovarian carcinogenesis and is providing “invaluable etiologic and clinical leads that promise to refine and improve both the prevention and management of ovarian cancer,” they write.
If you used Talcum powder and now have a cancer diagnosis contact us today